Closing the gap between clinical trials and routine care
High-cost innovative medicines often reach access and reimbursement processes with limited follow-up, small patient populations or uncertainty about long-term outcomes.
Health Systems must decide whether and how to provide access without knowing whether decision-grade evidence can be generated in routine care.
Manufacturers face similar uncertainty about evidence expectations, implementation requirements, negotiations and viable net launch pricing.
AIM4ALL creates a seamless link between clinical trials and routine care. This provides a more dependable, longitudinal basis for understanding a medicine's real-world value.
In collaboration with Remedium Capital and its finance partners, these insights can also support greater visibility of acceptable MFN net launch pricing.
Current challenge
Immature evidence at launch
Fragmented health data
Uncertain real-world outcomes
Repeated, one-off negotiations
Affordability pressure
Cross-border evidence requirement
AIM4ALL response
Earlier collection of payer-relevant data
Structured governance-compliant datasets
Longitudinal evidence before and after launch
Scalable service and contracting models
Better visibility of outcomes, value and pricing
Federated collaboration with national data control